A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET * What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET
Sponsor: NiKang Therapeutics, Inc.
You may qualify if…
- ✓ Able to provide written informed consent
- ✓ Advanced unresectable or metastatic solid tumor (Part 1, 2 \& 3 only)
- ✓ Advanced unresectable or metastatic HR+/HER2- breast cancer (Part 4 \& 5 only)
- ✓ Refractory to or unable to tolerate existing therapies (Part 1, 2 \& 4 only)
- ✓ Measurable or evaluable disease (Part 1, 2, \& 4 only).
- ✓ Measurable disease (Part 3 \& 5 only)
- ✓ Eighteen years of age or older
- ✓ ECOG status of 0 or 1
You may not qualify if…
- ✕ Advanced solid tumor that is a candidate for curative treatment
- ✕ History of another malignancy except for the following: adequately treated local basal cell or squamous carcinoma of the skin, in situ cervical cancer, adequately treated papillary noninvasive bladder cancer, other adequately treated Stage I or Stage II cancers currently in complete remission
- ✕ Not recovered from the effects of prior anticancer therapy
- ✕ Clinically significant cardiovascular event, including myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism, within 6 months
- ✕ Known active CNS metastases and/or carcinomatous meningitis
- ✕ Active interstitial lung disease requiring treatment
- ✕ History of uveitis, retinopathy, or other clinically significant retinal disease
- ✕ Major surgery within 30 days of administration of first dose
Where it's recruiting
Duarte · La Jolla
Denver
New Haven
Washington D.C.
Sarasota
Iowa City
Boston
Grand Rapids
St Louis
Las Vegas
Cleveland
Pittsburgh
Source: ClinicalTrials.gov · NCT07029399 · last updated 2026-11-05